Patents by Inventor Michael Mutz

Michael Mutz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120015955
    Abstract: The invention relates to the F-crystal form, G-crystal form, H-crystal form, I-crystal form and K-crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, certain processes for their preparation, pharmaceutical compositions containing these crystal forms, their use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, especially humans.
    Type: Application
    Filed: July 15, 2011
    Publication date: January 19, 2012
    Inventor: Michael Mutz
  • Publication number: 20110275685
    Abstract: The present invention relates to salts, polymorphs and hydrates of the kinesin inhibitor compound N-((S)-3-amino-4-fluorobutyl)-N-((R)-1-(1-benzlyl-4-(2,5-difluorophenyl)-1H-imidazol-2-yl)-2,2-dimethylpropyl)-2-hydroxyacetamide, processes to prepare such salts, polymorphs and hydrates and a liquid formulation comprising at least one of these salts, polymorphs and hydrates.
    Type: Application
    Filed: January 25, 2010
    Publication date: November 10, 2011
    Inventors: Michael Mutz, Jean-Louis Reber, Stephanie Monnier
  • Publication number: 20110229501
    Abstract: The present invention relates to crystalline forms and hydrates of 2-Amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol, and to the use thereof, in particular in the treatment or prevention of various autoimmune conditions.
    Type: Application
    Filed: November 10, 2009
    Publication date: September 22, 2011
    Applicant: NOVARTIS AG
    Inventors: Guido Jordine, Michael Mutz
  • Publication number: 20110218248
    Abstract: The present invention relates to salts, polymorphs and hydrates of 2-Amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol, and to the use thereof, in particular in the treatment or prevention of various autoimmune conditions.
    Type: Application
    Filed: November 10, 2009
    Publication date: September 8, 2011
    Inventors: Guido Jordine, Michael Mutz
  • Publication number: 20110171301
    Abstract: The invention relates to the F-crystal form, G-crystal form, H-crystal form, I-crystal form and K-crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, certain processes for their preparation, pharmaceutical compositions containing these crystal forms, their use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, especially humans.
    Type: Application
    Filed: January 14, 2011
    Publication date: July 14, 2011
    Inventor: Michael Mutz
  • Patent number: 7893076
    Abstract: The invention relates to the F-crystal form, G-crystal form, H-crystal form, I-crystal form and K-crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, certain processes for their preparation, pharmaceutical compositions containing these crystal forms, their use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, especially humans.
    Type: Grant
    Filed: November 23, 2006
    Date of Patent: February 22, 2011
    Assignees: Novartis AG, Novartis Pharma GmbH
    Inventor: Michael Mutz
  • Patent number: 7879860
    Abstract: The invention relates to the delta and epsilon crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2 -ylamino)phenyl]-benzamide (the compound of formula I, see below), certain processes for their preparation, pharmaceutical compositions containing these crystal forms, and their use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, especially humans.
    Type: Grant
    Filed: August 24, 2006
    Date of Patent: February 1, 2011
    Assignee: Novartis AG
    Inventor: Michael Mutz
  • Publication number: 20100286081
    Abstract: The invention relates to a maleate salt of 5-amino-3-(2?-3?-di-O-acetyl-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and crystalline forms thereof, their production and usage, and pharmaceutical preparations containing these crystalline forms.
    Type: Application
    Filed: May 21, 2007
    Publication date: November 11, 2010
    Inventors: Michael Mutz, Casper Volgel
  • Publication number: 20100197705
    Abstract: There is described a new polymorphic form of 4-(7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile having structural formula I(B) and to a method of preparing it. There is further a process or method for the manufacture of a pharmaceutically active quinazolinone compounds of the formula I wherein the symbols have the meanings given in the description, said process comprising reacting a compound of the formula II, wherein R4* is R1*—C(?O)— wherein R1* is independently selected from the group of meanings of R1 as defined for a compound of the formula I so that R1* and R1 are identical to or different from each other, or R4* is especially H, and R1 and R3, R5 and R6 are as defined for a compound of the formula I, or a salt thereof, under simultaneous or sequential condensation and cyclisation conditions with an aniline compound of the formula III, wherein R2 and m are as defined for a compound of the formula I. Further reactions and related embodiments are also claimed and disclosed.
    Type: Application
    Filed: January 6, 2010
    Publication date: August 5, 2010
    Inventors: Weichun Chen, Hong-Yong Kim, Jessica Liang, Michael Mutz, Mahavir Prashad, Christopher Towler, Ruoqiu Wu
  • Publication number: 20100178336
    Abstract: The invention relates to the stabilized amorphous form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N--[4-methyl-3-( 4-(pyridin-3-yl)-pyrimidin-2-ylamino)-phenyl]-benzamide, pharmaceutical compositions such as capsules or tablets containing this form, the use of such form in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and the use of formulation principles stabilizing the amorphous form of Imatinib mesylate as an intermediate for the preparation of pharmaceutical compositions.
    Type: Application
    Filed: June 5, 2008
    Publication date: July 15, 2010
    Applicant: NOVARTIS AG
    Inventors: Elisabete Goncalves, Oskar Kalb, Michael Mutz, Wolfgang Wirth, Jay Parthiban Lakshman
  • Publication number: 20100160393
    Abstract: The invention relates to new crystal forms of epothilone B.
    Type: Application
    Filed: August 14, 2007
    Publication date: June 24, 2010
    Applicant: NOVARTIS AG
    Inventors: Ernst Küsters, Michael Mutz, Frank Stowasser
  • Publication number: 20100093732
    Abstract: The present invention relates to new salt forms of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide, in particular the mesylate, hydrochloride, tartrate, phosphate and hemi fumarate salt thereof; to crystalline forms of such salts; to polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide; to hydrates and polymorphs of the new salt forms mentioned above; to the use of the new salt forms mentioned above for the manufacture of a medicament for the treatment of a disorder mediated by Hsp90; to a method for treating a disorder mediated by Hsp90 using the new salt forms; to formulations comprising such salt forms, in particular aqueous solutions suitable for intravenous administration; and to amber glass containers being filled with such formulations.
    Type: Application
    Filed: February 28, 2008
    Publication date: April 15, 2010
    Inventors: Martin James Drysdale, Brian William Dymock, Christoph Krell, Michael Mutz, Holger Petersen, Weijia Zheng
  • Patent number: 7683048
    Abstract: Polymorphic crystal forms of 3-methylthiophene-2-carboxylic acid (6S,9R,10S,11S,13S,16R, 17R)-9-chloro-6-fluoro-11-hydroxy-17-methoxycarbonyl-10,13,16-trimethyl-3-oxo-6,7,8,9,10, 11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl ester. The crystal forms possess anti-inflammatory activity and have very good stability. Methods for preparing the crystal forms are also described.
    Type: Grant
    Filed: July 28, 2003
    Date of Patent: March 23, 2010
    Assignee: Novartis AG
    Inventors: Guido Jordine, Michael Mutz
  • Publication number: 20100056481
    Abstract: The invention relates to new crystalline forms of low water soluble salts of zoledronic acid, the process for preparation of these crystalline forms, compositions containing these crystalline forms, and the use of these crystalline forms in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans. The invention relates to the crystalline form of the free acid monohydrate of zoledronic acid, the process for preparation of the crystalline form of the free acid monohydrate of zoledronic acid, compositions containing the crystalline form of the free acid monohydrate of zoledronic acid, and the use of crystalline form of the free acid monohydrate of zoledronic acid in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans.
    Type: Application
    Filed: November 26, 2007
    Publication date: March 4, 2010
    Inventors: Alexandra Glausch, Olivier Lohse, Michael Mutz, Holger Petersen, Juergen Sigg, Caspar Vogel, Hans-Joachim Weber
  • Publication number: 20100056590
    Abstract: The invention relates to crystalline forms of -[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid and to its amorphous form, to processes for the preparation thereof, to compositions containing the same and their uses for the manufacture of a medicament for the treatment of the human body.
    Type: Application
    Filed: November 27, 2007
    Publication date: March 4, 2010
    Applicant: NOVARTIC AG
    Inventor: Michael Mutz
  • Publication number: 20090326239
    Abstract: The invention relates to a new process for concentrating epothilones in culture media, a new process for the production of epothilones, a new process for separating epothilones A and B and a new strain obtained by mutagenesis for the production of epothilones, as well as aspects related thereto. New crystal forms of epothilone B are also described.
    Type: Application
    Filed: March 4, 2009
    Publication date: December 31, 2009
    Inventors: Hans Hofmann, Marion Mahnke, Klaus Memmert, Frank Petersen, Thomas Schupp, Ernst Kusters, Michael Mutz
  • Publication number: 20090137552
    Abstract: The invention relates to a new crystalline form II of N-benzoyl-staurosporine; compositions containing the same; processes for the preparation thereof; and the use of crystalline form II of N-benzoyl-staurosporine in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans. The invention relates to the amorphous forms of N-benzoyl-staurosporine; compositions containing the same; processes for the preparation thereof; and the use of amorphous N-benzoyl-staurosporine in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans.
    Type: Application
    Filed: November 3, 2005
    Publication date: May 28, 2009
    Inventors: Pascale Hoehn, Bernd Koch, Michael Mutz
  • Publication number: 20080268040
    Abstract: The invention relates to the F-crystal form, G-crystal form, H-crystal form, I-crystal form and K-crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, certain processes for their preparation, pharmaceutical compositions containing these crystal forms, their use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, especially humans.
    Type: Application
    Filed: November 3, 2006
    Publication date: October 30, 2008
    Inventor: Michael Mutz
  • Publication number: 20080254116
    Abstract: The invention relates to the delta and epsilon crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide (the compound of formula I, see below), certain processes for their preparation, pharmaceutical compositions containing these crystal forms, and their use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, especially humans.
    Type: Application
    Filed: August 24, 2006
    Publication date: October 16, 2008
    Inventor: Michael Mutz
  • Publication number: 20080249104
    Abstract: The present invention relates to acid addition salts of 4-[(4-methyl-1-piperazinyl)methyl]-N-(4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, which are selected from the group consisting of a tartrate salt, such as a (D)(?) tartrate salt or a (L)(+) tartrate salt, a hydrochloride salt, a citrate salt, a malate salt, a fumarate salt, a succinate salt, a benzoate salt, a benzenesulfonate salt, a pamoate salt, a formate salt, a malonate salt, a 1,5-naphthalenedisulfonate salt, a salicylate salt, a cyclohexanesulfamate salt, a lactate salt, a mandelate salt, aq glutarate salt, an adipate salt, a squarate salt, a vanillate salt, an oxaloacetate salt, an ascorbate salt and a sulfate salt.
    Type: Application
    Filed: February 3, 2005
    Publication date: October 9, 2008
    Inventors: Hans Michael Burger, Paul William Manley, Michael Mutz